First patient dosed in Phase 1/Phase 2 LION-CS101 trial of AB-1003 in August 2023, with enrollment continuing Asklepios ...
According to the Mayo Clinic, muscular dystrophy is a group of diseases that cause loss of muscle mass and progressive ...
New educational resources, and continued services and support are available through MDA’s Resource Center for family caregivers. November is National Family Caregivers Month Muscular Dystrophy ...
Wave Life Sciences Pte. Ltd ( (WVE) ) has released its Q3 earnings. Here is a breakdown of the information Wave Life Sciences Pte. Ltd ...
Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...
"For Duchenne muscular dystrophy, a devastating genetic disorder affecting young boys, securing both Orphan Drug and Rare Pediatric Disease Designations for Ifetroban from the FDA is a critical ...
Truist analyst Joon Lee raised the firm’s price target on Wave Life Sciences (WVE) to $36 from $17 and keeps a Buy rating on the shares.
The Muscular Dystrophy Association (MDA) proudly highlights National Family Caregivers Awareness Month this November. MDA's month-long campaign emphasizes the essential role caregivers ...
Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback